Rezolute, Inc. - (NV) (RZLT)
RZLT moved a median of -0.23% 30 minutes after news, and 0.00% by the close. How RZLT actually reacts to news — the realized, point-in-time move the market made, measured across 362 labeled events over the last three years with zero look-ahead.
RZLT’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.09% | 51% | 349 |
| 30-min | -0.23% | 44% | 361 |
| 60-min | -0.45% | 39% | 362 |
| to close | 0.00% | 48% | 362 |
| Middle 50% of RZLT reactions | -1.85% to +1.50% |
|---|---|
| Median reaction (30-min) | -0.23% |
| Measured reactions | 362 |
Half of all Rezolute, Inc. - (NV) news events land between -1.85% and +1.50% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How RZLT reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 12 | +0.46% | 58% | +4.57% |
| Analyst downgrades | 13 | +0.81% | 62% | +8.11% |
| Coverage initiations | 19 | -0.60% | 11% | -1.19% |
| Rating reiterations | 67 | +0.13% | 54% | +0.98% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how RZLT ranks against every other measured name →
That’s how RZLT usually reacts — get an email when it moves on news →Email me when RZLT moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to RZLT's baseline. Nothing else.
Recent RZLT events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Rezolute, Inc. For: Oct 14 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism | Press release | GlobeNewswire | — | — | |
| Form PRE 14A Rezolute, Inc. For: Dec 02 | SEC filing · Form PRE | SEC EDGAR | +1.25% | +7.16% | |
| Form 8-K Rezolute, Inc. For: Oct 05 | SEC filing · Form 8-K | SEC EDGAR | +1.60% | +6.91% | |
| Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinism | Press release | GlobeNewswire | +1.60% | +6.91% | |
| Form 10-K Rezolute, Inc. For: Jun 30 | SEC filing · Form 10-K | SEC EDGAR | -2.38% | -2.26% | |
| Form 8-K Rezolute, Inc. For: Sep 24 | SEC filing · Form 8-K | SEC EDGAR | -2.38% | -2.26% | |
| Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | -2.38% | -2.26% | |
| Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism | Press release | GlobeNewswire | +1.85% | -6.02% | |
| Rezolute to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +1.56% | +1.33% | |
| Rezolute to Participate in the BTIG Virtual Biotechnology Conference | Press release | GlobeNewswire | +0.22% | +12.36% | |
| Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society | Press release | GlobeNewswire | +1.30% | +3.46% | |
| Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society | Press release | GlobeNewswire | +2.21% | -0.44% | |
| Form 8-K Rezolute, Inc. For: Jun 02 | SEC filing · Form 8-K | SEC EDGAR | -3.09% | +7.53% | |
| Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism | Press release | GlobeNewswire | -3.09% | +7.53% | |
| Form 10-Q Rezolute, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.60% | +0.60% | |
| Form 8-K Rezolute, Inc. For: May 12 | SEC filing · Form 8-K | SEC EDGAR | +0.60% | +0.60% | |
| Rezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | +0.60% | +0.60% | |
| Rezolute to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.61% | -3.06% | |
| Form 8-K Rezolute, Inc. For: May 01 | SEC filing · Form 8-K | SEC EDGAR | -1.50% | -1.50% | |
| Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting | Press release | GlobeNewswire | +2.30% | +1.23% | |
| Rezolute to Present Results from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism at the Pediatric Endocrine Society (PES) Annual Meeting | Press release | GlobeNewswire | -1.19% | -2.09% | |
| Form 8-K Rezolute, Inc. For: Mar 24 | SEC filing · Form 8-K | SEC EDGAR | +1.21% | +8.47% | |
| Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting | Press release | GlobeNewswire | +1.21% | +8.47% | |
| Rezolute to Participate in the Citizens Life Sciences Conference | Press release | GlobeNewswire | -0.68% | +5.47% | |
| Form 10-Q Rezolute, Inc. For: Dec 31 | SEC filing · Form 10-Q | SEC EDGAR | +4.43% | +6.37% | |
| Form 8-K Rezolute, Inc. For: Feb 12 | SEC filing · Form 8-K | SEC EDGAR | +4.43% | +6.37% | |
| Rezolute Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | +4.43% | +6.37% | |
| Rezolute to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 | Press release | GlobeNewswire | -0.95% | -7.91% | |
| Form 8-K Rezolute, Inc. For: Jan 07 | SEC filing · Form 8-K | SEC EDGAR | +9.00% | +17.50% | |
| Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism | Press release | GlobeNewswire | +9.00% | +17.50% | |
| Rezolute Announces Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism | Press release | GlobeNewswire | +14.05% | +15.70% | |
| Form S-3ASR Rezolute, Inc. | SEC filing · Form S-3ASR | SEC EDGAR | -0.33% | -2.49% | |
| Form 8-K Rezolute, Inc. For: Nov 19 | SEC filing · Form 8-K | SEC EDGAR | +1.83% | -0.61% | |
| Form S-8 Rezolute, Inc. | SEC filing · Form S-8 | SEC EDGAR | +1.83% | -0.61% | |
| Form 8-K Rezolute, Inc. For: Nov 10 | SEC filing · Form 8-K | SEC EDGAR | +0.75% | -0.20% | |
| Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.20% | +0.40% | |
| Form 10-Q Rezolute, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.90% | +13.86% | |
| Form 8-K Rezolute, Inc. For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | +0.90% | +13.86% | |
| Rezolute Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | +0.90% | +13.86% | |
| Rezolute to Host Virtual Investor Event on Ersodetug Development Program | Press release | GlobeNewswire | +0.67% | +3.89% | |
| Form 8-K Rezolute, Inc. For: Oct 17 | SEC filing · Form 8-K | SEC EDGAR | +6.75% | +7.90% | |
| Rezolute to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +1.24% | +5.88% | |
| Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.03% | -6.02% | |
| Form DEF 14A Rezolute, Inc. For: Nov 19 | SEC filing · Form DEF | SEC EDGAR | +0.34% | -0.91% | |
| Form 10-K Rezolute, Inc. For: Jun 30 | SEC filing · Form 10-K | SEC EDGAR | +0.33% | +6.49% | |
| Form 8-K Rezolute, Inc. For: Sep 17 | SEC filing · Form 8-K | SEC EDGAR | +0.33% | +6.49% | |
| Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | +0.33% | +6.49% | |
| Form 8-K Rezolute, Inc. For: Sep 02 | SEC filing · Form 8-K | SEC EDGAR | +1.01% | +0.70% | |
| Rezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism | Press release | GlobeNewswire | +1.01% | +0.70% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the RZLT section they belong to.
Where else RZLT is measured.
RZLT earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Tenet Healthcare Corporation (THC) | 363 | +0.22% | 60% |
| Vanda Pharmaceuticals Inc. (VNDA) | 363 | -0.22% | 44% |
| Erytech Pharma S.A. - American Depositary Shares (ERYP) | 360 | 0.00% | 29% |
| AQUINOX PHARMACEUTICALS (AQXP) | 357 | 0.00% | 46% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Rezolute, Inc. - (NV)'s median reaction calculated?
Every labeled RZLT news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 362 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 44% of RZLT's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does RZLT's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.